外泌体在消化系统肿瘤早期诊断中的进展
Advances in Exosomes in the Early Diagnosis of Digestive System Tumor
DOI: 10.12677/acm.2024.1482180, PDF,    科研立项经费支持
作者: 谭聪聪*, 黄鸿才:成都中医药大学医学与生命科学学院,四川 成都;遂宁市中心医院肝胆外科,四川 遂宁;戴 毅:遂宁市中心医院肝胆外科,四川 遂宁;余 华#:成都中医药大学附属医院普外科,四川 成都
关键词: 外泌体消化系统肿瘤早期诊断食管癌胃癌结直肠癌肝癌Exosomes Digestive System Tumors Early Diagnosis Esophageal Cancer Gastric Cancer Colorectal Cancer Liver Cancer
摘要: 目的:总结外泌体在消化系统肿瘤(Digestive system tumor)早期诊断中的应用研究进展,为后续相关研究提供思路与方法,便于相关研究尽快转化为临床应用。方法:阅读国内外外泌体在消化系统肿瘤研究的相关文献,进行整理、总结并综述。结果:目前,消化系统肿瘤是当前肿瘤相关死亡常见的病因之一且发病年龄趋年轻化。外泌体(Exosomes)可在分子间通讯发挥巨大作用,对外泌体的检测可达到对消化系统肿瘤的早期诊断,这对于该类肿瘤患者的治疗及预后有重要意义。结论:外泌体检测在消化系统肿瘤早期诊断是可行的,相关研究方法与技术正在向临床应用转化。
Abstract: Objective: To summarize the research progress on the application of exosomes in the early diagnosis of digestive system tumors, to provide ideas and methods for the subsequent related research, and to facilitate the translation of related research into clinical application as soon as possible. Methods: The literatures related to the study of exosomes in digestive system tumors at home and abroad were reviewed, organized, summarized and synthesized. Results: Currently, digestive system tumors are the most common cause of tumor-related deaths and the age of onset tends to be younger. Exosomes can play a huge role in intermolecular communication, detection of exosomes can achieve early diagnosis of digestive system tumors, which is important for the treatment and prognosis of patients with this type of tumor. Conclusions: Exosome detection is feasible in the early diagnosis of digestive system tumors, and the related research methods and techniques are being translated into clinical applications.
文章引用:谭聪聪, 黄鸿才, 戴毅, 余华. 外泌体在消化系统肿瘤早期诊断中的进展[J]. 临床医学进展, 2024, 14(8): 47-56. https://doi.org/10.12677/acm.2024.1482180

参考文献

[1] Arnold, M., Abnet, C.C., Neale, R.E., Vignat, J., Giovannucci, E.L., McGlynn, K.A., et al. (2020) Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology, 159, 335-349.e15. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, X., Gole, J., Gore, A., He, Q., Lu, M., Min, J., et al. (2020) Non-Invasive Early Detection of Cancer Four Years before Conventional Diagnosis Using a Blood Test. Nature Communications, 11, Article No. 3475. [Google Scholar] [CrossRef] [PubMed]
[3] Najafi, S., Majidpoor, J. and Mortezaee, K. (2024) Liquid Biopsy in Colorectal Cancer. Clinica Chimica Acta, 553, Article ID: 117674. [Google Scholar] [CrossRef] [PubMed]
[4] Huang, Z., Zhu, D., Wu, L., He, M., Zhou, X., Zhang, L., et al. (2017) Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer. Cancer Epidemiology, Biomarkers & Prevention, 26, 188-196. [Google Scholar] [CrossRef] [PubMed]
[5] Deboever, N., Jones, C.M., Yamashita, K., Ajani, J.A. and Hofstetter, W.L. (2024) Advances in Diagnosis and Management of Cancer of the Esophagus. BMJ, 385, e074962. [Google Scholar] [CrossRef] [PubMed]
[6] Qu, J., Li, Y., Liu, G., Li, Z., Zhong, N., Zhang, M., et al. (2023) Optimal Concentration of Lugol’s Solution for Detecting Early Esophageal Carcinoma: A Randomized Controlled Trial. Journal of Gastroenterology and Hepatology, 38, 962-969. [Google Scholar] [CrossRef] [PubMed]
[7] Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., et al. (2012) Clinical Impact of Serum Exosomal Microrna‐21 as a Clinical Biomarker in Human Esophageal Squamous Cell Carcinoma. Cancer, 119, 1159-1167. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, L., Liu, H., Wu, Q., Liu, Y., Yan, Z., Chen, G., et al. (2024) miR-451a Was Selectively Sorted into Exosomes and Promoted the Progression of Esophageal Squamous Cell Carcinoma through CAB39. Cancer Gene Therapy, 31, 1060-1069. [Google Scholar] [CrossRef] [PubMed]
[9] Xu, M., Liu, T., Dong, F., Meng, L., Ling, A. and Liu, S. (2021) Exosomal Lncrna LINC01711 Facilitates Metastasis of Esophageal Squamous Cell Carcinoma via the miR-326/FSCN1 Axis. Aging, 13, 19776-19788. [Google Scholar] [CrossRef] [PubMed]
[10] Rao, D., Lu, H., Wang, X., Lai, Z., Zhang, J. and Tang, Z. (2023) Tissue-Derived Exosome Proteomics Identifies Promising Diagnostic Biomarkers for Esophageal Cancer. eLife, 12, e86209. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, C., Guo, Z. and Jing, Z. (2024) Prediction of Response to Chemoradiotherapy by Dynamic Changes of Circulating Exosome Levels in Patients with Esophageal Squamous Cell Carcinoma. International Journal of Nanomedicine, 19, 1351-1362. [Google Scholar] [CrossRef] [PubMed]
[12] Xie, C., Chen, X., Chen, Y., Wang, X., Zuo, J., Zheng, A., et al. (2023) Mutual Communication between Radiosensitive and Radioresistant Esophageal Cancer Cells Modulates Their Radiosensitivity. Cell Death & Disease, 14, Article No. 846. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Z., Zhang, M., Liu, L., Yang, Y., Qiu, J., Yu, Y., et al. (2023) Prognostic and Immunological Role of Cancer-Associated Fibroblasts-Derived Exosomal Protein in Esophageal Squamous Cell Carcinoma. International Immunopharmacology, 124, Article ID: 110837. [Google Scholar] [CrossRef] [PubMed]
[14] Yan, D., Cui, D., Zhu, Y., Chan, C.K.W., Choi, C.H.J., Liu, T., et al. (2023) M6PR-And EphB4-Rich Exosomes Secreted by Serglycin-Overexpressing Esophageal Cancer Cells Promote Cancer Progression. International Journal of Biological Sciences, 19, 625-640. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, X. and Zhang, P. (2016) Gastric Cancer: Somatic Genetics as a Guide to Therapy. Journal of Medical Genetics, 54, 305-312. [Google Scholar] [CrossRef] [PubMed]
[16] Fujishiro, M. (2024) Advanced Diagnostic and Therapeutic Endoscopy for Early Gastric Cancer. Cancers, 16, Article 1039. [Google Scholar] [CrossRef] [PubMed]
[17] Shen, M., Wang, H., Wei, K., Zhang, J. and You, C. (2018) Five Common Tumor Biomarkers and CEA for Diagnosing Early Gastric Cancer: A Protocol for a Network Meta-Analysis of Diagnostic Test Accuracy. Medicine, 97, e0577. [Google Scholar] [CrossRef] [PubMed]
[18] Yang, A., Liu, J., Lei, H., Zhang, Q., Zhao, L. and Yang, G. (2014) CA72-4 Combined with CEA, CA125 and CAL9-9 Improves the Sensitivity for the Early Diagnosis of Gastric Cancer. Clinica Chimica Acta, 437, 183-186. [Google Scholar] [CrossRef] [PubMed]
[19] Shimada, H., Noie, T., Ohashi, M., Oba, K. and Takahashi, Y. (2013) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systematic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, Y., Wang, B., Zhao, Y., Shao, X., Wang, M., Ma, F., et al. (2024) Metabolomic Machine Learning Predictor for Diagnosis and Prognosis of Gastric Cancer. Nature Communications, 15, Article No. 1657. [Google Scholar] [CrossRef] [PubMed]
[21] Li, S., Zhang, M., Zhang, H., Hu, K., Cai, C., Wang, J., et al. (2020) Exosomal Long Noncoding RNA Lnc-GNAQ-6:1 May Serve as a Diagnostic Marker for Gastric Cancer. Clinica Chimica Acta, 501, 252-257. [Google Scholar] [CrossRef] [PubMed]
[22] Sun, Y., Jin, J., Jing, H., Lu, Y., Zhu, Q., Shu, C., et al. (2021) ITIH4 Is a Novel Serum Biomarker for Early Gastric Cancer Diagnosis. Clinica Chimica Acta, 523, 365-373. [Google Scholar] [CrossRef] [PubMed]
[23] Zheng, G., Xu, Z., Hu, C., Lv, H., Xie, H., Huang, T., et al. (2021) Exosomal miR-590-5p in Serum as a Biomarker for the Diagnosis and Prognosis of Gastric Cancer. Frontiers in Molecular Biosciences, 8, Article 636566. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, H., Zeng, X., Zheng, Y., Wang, Y. and Zhou, Y. (2021) Exosomal Circrna in Digestive System Tumors: The Main Player or Coadjuvants? Frontiers in Oncology, 11, Article 614462. [Google Scholar] [CrossRef] [PubMed]
[25] Song, Q., Lv, X., Ru, Y., Dong, J., Chang, R., Wu, D., et al. (2022) Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Noninvasive Biomarker for Predicting Chemotherapy Response and Prognosis of Advanced Gastric Cancer: A Multi-Cohort, Multi-Phase Study. eBioMedicine, 78, Article ID: 103971. [Google Scholar] [CrossRef] [PubMed]
[26] Tang, X., Guo, T., Gao, X., Wu, X., Xing, X., Ji, J., et al. (2021) Exosome-Derived Noncoding Rnas in Gastric Cancer: Functions and Clinical Applications. Molecular Cancer, 20, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[27] Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. [Google Scholar] [CrossRef] [PubMed]
[28] Wolf, A.M.D., Fontham, E.T.H., Church, T.R., Flowers, C.R., Guerra, C.E., LaMonte, S.J., et al. (2018) Colorectal Cancer Screening for Average‐risk Adults: 2018 Guideline Update from the American Cancer Society. CA: A Cancer Journal for Clinicians, 68, 250-281. [Google Scholar] [CrossRef] [PubMed]
[29] Zhao, S., Wang, S., Pan, P., Xia, T., Chang, X., Yang, X., et al. (2019) Magnitude, Risk Factors, and Factors Associated with Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-Analysis. Gastroenterology, 156, 1661-1674.E11. [Google Scholar] [CrossRef] [PubMed]
[30] Dong, X., Du, L., Luo, Z., Xu, Y., Wang, C., Wang, F., et al. (2024) Combining Fecal Immunochemical Testing and Questionnaire-Based Risk Assessment in Selecting Participants for Colonoscopy Screening in the Chinese National Colorectal Cancer Screening Programs: A Population-Based Cohort Study. PLOS Medicine, 21, e1004340. [Google Scholar] [CrossRef] [PubMed]
[31] Yen, A.M., Hsu, C., Lin, T., Su, C., Chiu, H., Chen, T.H., et al. (2024) Precision Colorectal Cancer Fecal Immunological Test Screening with Fecal-Hemoglobin-Concentration-Guided Interscreening Intervals. JAMA Oncology, 10, 765-772. [Google Scholar] [CrossRef] [PubMed]
[32] Ladabaum, U., Dominitz, J.A., Kahi, C. and Schoen, R.E. (2020) Strategies for Colorectal Cancer Screening. Gastroenterology, 158, 418-432. [Google Scholar] [CrossRef] [PubMed]
[33] Yoon, J.H., Yu, M.H., Hur, B.Y., Park, C.M. and Lee, J.M. (2020) Detection of Distant Metastases in Rectal Cancer: Contrast-Enhanced CT vs Whole Body MRI. European Radiology, 31, 104-111. [Google Scholar] [CrossRef] [PubMed]
[34] Meyer, M., Ronald, J., Vernuccio, F., Nelson, R.C., Ramirez-Giraldo, J.C., Solomon, J., et al. (2019) Reproducibility of CT Radiomic Features within the Same Patient: Influence of Radiation Dose and CT Reconstruction Settings. Radiology, 293, 583-591. [Google Scholar] [CrossRef] [PubMed]
[35] Hao, C., Sui, Y., Li, J., Shi, Y. and Zou, Z. (2021) The Clinical Value of the Combined Detection of Enhanced CT, MRI, CEA, and CA199 in the Diagnosis of Rectal Cancer. Journal of Oncology, 2021, Article ID: 8585371. [Google Scholar] [CrossRef] [PubMed]
[36] Min, L., Zhu, S., Chen, L., Liu, X., Wei, R., Zhao, L., et al. (2019) Evaluation of Circulating Small Extracellular Vesicles Derived miRNAs as Biomarkers of Early Colon Cancer: A Comparison with Plasma Total miRNAs. Journal of Extracellular Vesicles, 8, Article ID: 1643670. [Google Scholar] [CrossRef] [PubMed]
[37] Wu, Y., Zhang, J., Lin, F., Zhao, Y., Zheng, B., Zhou, N., et al. (2024) Exosomal miR‐1470 Is a Diagnostic Biomarker and Promotes Cell Proliferation and Metastasis in Colorectal Cancer. Cancer Medicine, 13, e7117. [Google Scholar] [CrossRef] [PubMed]
[38] Wang, D., Wang, X., Si, M., Yang, J., Sun, S., Wu, H., et al. (2020) Exosome-encapsulated miRNAs Contribute to Cxcl12/cxcr4-Induced Liver Metastasis of Colorectal Cancer by Enhancing M2 Polarization of Macrophages. Cancer Letters, 474, 36-52. [Google Scholar] [CrossRef] [PubMed]
[39] Liang, G., Zhu, Y., Ali, D.J., Tian, T., Xu, H., Si, K., et al. (2020) Engineered Exosomes for Targeted Co-Delivery of miR-21 Inhibitor and Chemotherapeutics to Reverse Drug Resistance in Colon Cancer. Journal of Nanobiotechnology, 18, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[40] Magliacane Trotta, S., Adinolfi, A., D’Orsi, L., Panico, S., Mercadante, G., Mehlen, P., et al. (2024) Cancer-Derived Exosomal Alu RNA Promotes Colorectal Cancer Progression. Experimental & Molecular Medicine, 56, 700-710. [Google Scholar] [CrossRef] [PubMed]
[41] Yu, X., Bu, C., Yang, X., Jiang, W., He, X., Sun, R., et al. (2024) Exosomal Non-Coding RNAs in Colorectal Cancer Metastasis. Clinica Chimica Acta, 556, Article ID: 117849. [Google Scholar] [CrossRef] [PubMed]
[42] Al-Joufi, F., Setia, A., Salem-Bekhit, M., Sahu, R., Alqahtani, F., Widyowati, R., et al. (2022) Molecular Pathogenesis of Colorectal Cancer with an Emphasis on Recent Advances in Biomarkers, as Well as Nanotechnology-Based Diagnostic and Therapeutic Approaches. Nanomaterials, 12, Article 169. [Google Scholar] [CrossRef] [PubMed]
[43] Li, J., Zhang, G., Liu, C., Xiang, X., Le, M.T.N., Sethi, G., et al. (2022) The Potential Role of Exosomal Circrnas in the Tumor Microenvironment: Insights into Cancer Diagnosis and Therapy. Theranostics, 12, 87-104. [Google Scholar] [CrossRef] [PubMed]
[44] Hoshino, A., Kim, H.S., Bojmar, L., Gyan, K.E., Cioffi, M., Hernandez, J., et al. (2020) Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 182, 1044-1061.E18. [Google Scholar] [CrossRef] [PubMed]
[45] Liang, J.Q., Li, T., Nakatsu, G., Chen, Y., Yau, T.O., Chu, E., et al. (2019) A Novel Faecal Lachnoclostridium Marker for the Non-Invasive Diagnosis of Colorectal Adenoma and Cancer. Gut, 69, 1248-1257. [Google Scholar] [CrossRef] [PubMed]
[46] Grady, W.M., Yu, M. and Markowitz, S.D. (2021) Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology, 160, 690-709. [Google Scholar] [CrossRef] [PubMed]
[47] Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., et al. (2020) Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 9, 682-720. [Google Scholar] [CrossRef] [PubMed]
[48] Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. [Google Scholar] [CrossRef] [PubMed]
[49] Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A.X., Finn, R.S., Abecassis, M.M., et al. (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68, 723-750. [Google Scholar] [CrossRef] [PubMed]
[50] Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., et al. (2021) Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 10, 181-223. [Google Scholar] [CrossRef] [PubMed]
[51] Kubo, S., Shinkawa, H., Asaoka, Y., Ioka, T., Igaki, H., Izumi, N., et al. (2022) Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. Liver Cancer, 11, 290-314. [Google Scholar] [CrossRef] [PubMed]
[52] Tzartzeva, K., Obi, J., Rich, N.E., Parikh, N.D., Marrero, J.A., Yopp, A., et al. (2018) Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis: A Meta-Analysis. Gastroenterology, 154, 1706-1718.E1. [Google Scholar] [CrossRef] [PubMed]
[53] Sanduzzi-Zamparelli, M., Mariño, Z., Lens, S., Sapena, V., Iserte, G., Pla, A., et al. (2022) Liver Cancer Risk after HCV Cure in Patients with Advanced Liver Disease without Non-Characterized Nodules. Journal of Hepatology, 76, 874-882. [Google Scholar] [CrossRef] [PubMed]
[54] Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., et al. (2022) BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update. Journal of Hepatology, 76, 681-693. [Google Scholar] [CrossRef] [PubMed]
[55] Singal, A.G., Lampertico, P. and Nahon, P. (2020) Epidemiology and Surveillance for Hepatocellular Carcinoma: New Trends. Journal of Hepatology, 72, 250-261. [Google Scholar] [CrossRef] [PubMed]
[56] Xie, D., Ren, Z., Zhou, J., Fan, J. and Gao, Q. (2020) 2019 Chinese Clinical Guidelines for the Management of Hepatocellular Carcinoma: Updates and Insights. Hepatobiliary Surgery and Nutrition, 9, 452-463. [Google Scholar] [CrossRef] [PubMed]
[57] Heimbach, J.K., Kulik, L.M., Finn, R.S., Sirlin, C.B., Abecassis, M.M., Roberts, L.R., et al. (2017) AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67, 358-380. [Google Scholar] [CrossRef] [PubMed]
[58] Ahn, J.C., Teng, P., Chen, P., Posadas, E., Tseng, H., Lu, S.C., et al. (2021) Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology, 73, 422-436. [Google Scholar] [CrossRef] [PubMed]
[59] Gupta, S. (2003) Test Characteristics of Α-Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C: A Systematic Review and Critical Analysis. Annals of Internal Medicine, 139, 46-50. [Google Scholar] [CrossRef] [PubMed]
[60] Wei, X., Liu, L. and Zhu, F. (2022) Exosomes as Potential Diagnosis and Treatment for Liver Cancer. World Journal of Gastrointestinal Oncology, 14, 334-347. [Google Scholar] [CrossRef] [PubMed]
[61] Wang, J., Wang, X., Zhang, X., Shao, T., Luo, Y., Wang, W., et al. (2022) Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges. Frontiers in Oncology, 12, Article 884369. [Google Scholar] [CrossRef] [PubMed]
[62] Lee, Y., Tran, B.V., Wang, J.J., Liang, I.Y., You, S., Zhu, Y., et al. (2021) The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers, 13, Article 3076. [Google Scholar] [CrossRef] [PubMed]
[63] Melo, S.A., Sugimoto, H., O’Connell, J.T., Kato, N., Villanueva, A., Vidal, A., et al. (2014) Cancer Exosomes Perform Cell-Independent Microrna Biogenesis and Promote Tumorigenesis. Cancer Cell, 26, 707-721. [Google Scholar] [CrossRef] [PubMed]
[64] Lin, H.T., Castaneda, A.F.A., Krishna, S.G. and Mumtaz, K. (2024) microRNAs in Hepatocellular Carcinoma Treatment: Charting the Path Forward. World Journal of Gastroenterology, 30, 1470-1474. [Google Scholar] [CrossRef] [PubMed]
[65] Ghosh, S., Bhowmik, S., Majumdar, S., Goswami, A., Chakraborty, J., Gupta, S., et al. (2020) The Exosome Encapsulated microRNAs as Circulating Diagnostic Marker for Hepatocellular Carcinoma with Low α‐Fetoprotein. International Journal of Cancer, 147, 2934-2947. [Google Scholar] [CrossRef] [PubMed]
[66] Sorop, A., Constantinescu, D., Cojocaru, F., Dinischiotu, A., Cucu, D. and Dima, S.O. (2021) Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 22, Article 4997. [Google Scholar] [CrossRef] [PubMed]
[67] Aydin, Y., Koksal, A.R., Thevenot, P., Chava, S., Heidari, Z., Lin, D., et al. (2021) Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. Journal of Hepatocellular Carcinoma, 8, 1579-1596. [Google Scholar] [CrossRef] [PubMed]
[68] Xing, M., Wang, X., Kirken, R., He, L. and Zhang, J. (2021) Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International Journal of Molecular Sciences, 22, Article 6139. [Google Scholar] [CrossRef] [PubMed]
[69] Qu, C., Wang, Y., Wang, P., Chen, K., Wang, M., Zeng, H., et al. (2019) Detection of Early-Stage Hepatocellular Carcinoma in Asymptomatic HBsAG-Seropositive Individuals by Liquid Biopsy. Proceedings of the National Academy of Sciences of the United States of America, 116, 6308-6312. [Google Scholar] [CrossRef] [PubMed]
[70] Zhu, L., Li, J., Gong, Y., Wu, Q., Tan, S., Sun, D., et al. (2019) Exosomal tRNA-Derived Small RNA as a Promising Biomarker for Cancer Diagnosis. Molecular Cancer, 18, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[71] Liu, W., Li, J., Zhang, P., Hou, Q., Feng, S., Liu, L., et al. (2019) A Novel Pan‐Cancer Biomarker Plasma Heat Shock Protein 90αand Its Diagnosis Determinants in Clinic. Cancer Science, 110, 2941-2959. [Google Scholar] [CrossRef] [PubMed]
[72] Lei, X., Zhang, M., Guan, B., Chen, Q., Dong, Z. and Wang, C. (2021) Identification of Hub Genes Associated with Prognosis, Diagnosis, Immune Infiltration and Therapeutic Drug in Liver Cancer by Integrated Analysis. Human Genomics, 15, Article No. 39. [Google Scholar] [CrossRef] [PubMed]